Connect with us

Government

Bipartisan Senate Bill Would Give ‘Right to Try’ Protection to Psilocybin and MDMA

Published

on

Sen. Cory Booker of New Jersey and Sen. Rand Paul of Kentucky have introduced bipartisan legislation to extend Right to Try protection to drugs that have completed a Phase 1 clinical trial, including psilocybin and MDMA.

Democratic Senator Cory Booker of New Jersey and Senator Rand Paul, a Republican from Kentucky, introduced bipartisan legislation on Wednesday to extend federal Right to Try protection to the psychedelic drugs psilocybin and MDMA. Under the bill, titled the Right to Try Clarification Act, restrictions of the federal Controlled Substances Act would not apply to Schedule I Drugs for which a Phase 1 clinical trial has been completed. The new provisions would apply to doctors and patients with life-threatening medical conditions using Schedule 1 controlled substances under the federal Right to Try Act.

“As a physician, I know how important Right to Try is for patients facing a life-threatening condition,” Paul said in a statement about the legislation from Booker’s office. “Unfortunately, the federal bureaucracy continues to block patients seeking to use Schedule I drugs under Right to Try. I’m proud to lead this bipartisan legislation with Sen. Booker that will get government out of the way and give doctors more resources to help patients.”

The Right to Try Act allows patients who have been diagnosed with life-threatening diseases or conditions for which traditional therapies have not been effective to use certain treatments that have not yet been approved by the U.S. Food and Drug Administration. In most cases, a drug is eligible for Right to Try use after a Phase 1 clinical trial has been completed for that drug but before the drug is approved or licensed by the FDA for any use. Under the provisions of the Right to Try law, states have the option to permit or prohibit Right to Try use under state law.

The senators noted that two drugs, MDMA and psilocybin, show promise as treatment for a variety of mental health conditions, including depression, anxiety, and PTSD. The success and safety of the drugs exhibited in Phase 1 and Phase 2 clinical trials has been so encouraging that the FDA has classified both substances as “breakthrough therapies,” indicating that they show a substantial improvement over currently approved therapies.

“Recent studies suggest that MDMA and psilocybin could represent an enormous advancement in mental health and psychopharmacology,” said Booker. “Unfortunately, many eligible patients who urgently need care do not currently have access to these promising therapies. This legislation will put the patient first and help ensure access to life-changing and life-saving drugs.”

Companion Measure To Be Introduced in the House

A bipartisan duo of members of the House of Representatives who support federal cannabis policy have already signed on to support Booker and Paul’s bill and will introduce companion legislation in the House. Democratic Representative Earl Blumenauer of Oregon, who has long supported reforming the nation’s cannabis laws, and Representative Nancy Mace, a first-term Republican who introduced a bill to legalize cannabis last year, expressed their support for the change to Right to Try legislation.

“Oregon has a long legacy of ensuring that end-of-life patients have access to the full spectrum of treatment options to alleviate their condition and improve their quality of life. Patients and doctors deserve to discuss treatments—including psilocybin—that researchers find provide immediate and sustained relief from pain, anxiety, and depression for people battling terminal illness,” Blumenauer said. “Federal restrictions have obstructed access to end-of-life care for too long, this legislation will change that and ensure that all patients have the Right to Try. I appreciate Senator Booker’s leadership, it is timely and important.”

“Advances in science and technology are often made when we think outside the box and try new things,” said Mace. “This legislation gives patients the power to choose alternative options like psilocybin or MDMA when facing a life-threatening condition. We know these chemicals have the potential to save lives, and today is an important step forward in medical progress. I want to thank Senators Booker and Paul for their bipartisan work to bring these exciting new options into the mainstream medical world.”

The Right to Try Clarification Act was introduced in the Senate only one day before Booker, Senate Majority Leader Chuck Schumer of New York and Democratic Senator Ron Wyden of Oregon introduced a long-anticipated bill to legalize cannabis at the federal level. Shane Pennington, an attorney with the law firm Vicente Sederberg, said that he is “happy to see Congress paying attention to psychedelics issues, particularly those that affect the veteran community. Vets shouldn’t have to go to other countries to access therapies that evidence has shown to be safe and likely effective.”

Source: https://hightimes.com/news/bipartisan-senate-bill-would-give-right-to-try-protection-to-psilocybin-and-mdma/

Corruption

Vigilance Arrests Officials After Bribery Complaints at Supply Office

Published

on

By

HARIDWAR, Uttarakhand — Officials from the Dehradun-based Vigilance Department have arrested Haridwar District Supply Officer Shyam Arya and two other employees on charges of accepting a bribe of ₹50,000, authorities confirmed. The arrests took place during a planned operation after investigators laid a trap at the District Supply Office in response to repeated complaints from the public.

According to vigilance sources, the accused were caught “red-handed” while receiving the alleged bribe, reportedly demanded in exchange for official services within the department. The operation, coordinated from the state capital of Dehradun, underscores the department’s commitment to tackling corruption.

Complaints That Triggered the Operation
The arrests followed months of complaints alleging that officials at the Haridwar District Supply Office were routinely soliciting illegal payments for government services. These included the issuance of ration cards, approvals for licenses, and other administrative clearances under the public distribution system.

Vigilance officials said preliminary verification of the complaints indicated a recurring pattern rather than isolated incidents. Following this assessment, the department used a standard anti-corruption tactic of laying a trap to obtain direct evidence of bribe solicitation and acceptance.

Inside the Supply Office
After the arrests, vigilance teams established a presence inside the office, sealing parts of the premises while examining files and records. Investigators are reviewing documentation related to recent approvals and transactions to determine whether the alleged bribery was systemic.

The accused are also being questioned to identify potential accomplices and to ascertain whether accepting bribes was a routine practice. Officials noted that the investigation could expand depending on findings from the document review and interrogations.

A Broader Anti-Corruption Push
The case has drawn attention across Uttarakhand’s administrative machinery, particularly within the Supply Department, which plays a vital role in delivering welfare services. Vigilance officials said the arrests reflect a “zero-tolerance” approach toward corruption and warned that similar operations will continue wherever credible complaints arise.

The state’s anti-corruption drives have intensified in recent months, emphasizing both deterrence and accountability. While the investigation in Haridwar remains in its early stages, officials say it highlights the risks faced by public servants accused of exploiting their positions and the growing willingness of enforcement agencies to act on citizen complaints.

Continue Reading

Business

A Tipping Point for Cannabis: President Trump Champions CBD & Cannabis Science on Truth Social

Published

on

By

When the President of the United States shares a video about the life changing potential of hemp derived CBD on his personal social media platform, it is more than news, it is a cultural shift.

For decades our government lied to us about cannabis. It demonized the plant, waged war on its users, and filled prisons while allowing pharmaceutical companies to flood the nation with addictive and deadly drugs. For over a century we have been fighting uphill, not just for legalization, but for truth, for science, and for the right to heal ourselves naturally.

Now in 2025, the most powerful political figure on Earth is using his own voice and platform to talk about the endocannabinoid system and the science backed benefits of CBD. That is monumental. It is validation for everyone who has fought, been arrested, been silenced, and been dismissed for telling this truth. The President’s video post is already being described as a pivotal moment in cannabis history, and President Trump CBD Cannabis Science Truth Social is trending across platforms as advocates celebrate the breakthrough.


The Science Behind the Endocannabinoid System

The video begins by introducing something most people, including many doctors, still know little about, the endocannabinoid system. Discovered in the 1990s, the ECS is a network of receptors and signaling molecules that works as the body’s master regulator, coordinating communication between major systems like the nervous, immune, cardiovascular, and digestive systems.

The roots of this discovery go back much further. CBD was first isolated in 1940 by American chemist Roger Adams, but it was Dr. Raphael Mechoulam, an Israeli organic chemist, who fully elucidated the chemical structure of CBD and identified its stereochemistry in the 1960s. His pioneering work not only opened the door to modern cannabinoid science but also earned him the title “Godfather of Cannabis Research.” It was this foundation that led to the identification of the endocannabinoid system itself decades later, revealing how cannabinoids interact with our physiology on a fundamental level.

The ECS is now widely recognized as a vital part of human biology, with extensive research supported by the National Institutes of Health. When functioning properly, the ECS acts like the conductor of an orchestra, ensuring every section plays in harmony. As we age, the system weakens. That imbalance is linked to inflammation, chronic pain, cognitive decline, sleep problems, and many other conditions associated with aging.

Mainstream medicine often addresses these issues with pharmaceutical band aids, dangerous and addictive drugs that treat symptoms rather than root causes. Lifestyle changes such as diet and exercise help, but they only partially support the ECS and do so slowly over time.


Hemp Derived CBD: A Game Changer for Aging

Here is where the science gets exciting. As the video explains, the ECS can be restored much more quickly with hemp derived CBD. Strengthening this system naturally helps the body regain balance, reducing pain, improving sleep, lowering stress, slowing disease progression, and even extending healthy lifespan.

It is not theoretical. One in five seniors is already using CBD to manage pain, arthritis, cancer symptoms, sleep disorders, Alzheimer’s, and more. Despite decades of research and acknowledgment from institutions like the National Institutes of Health, most physicians receive no training on the ECS. There are still no FDA standards for CBD products on the market. If that were the case for any other class of medicine, it would be considered malpractice.

The World Health Organization has confirmed CBD’s excellent safety profile and non addictive nature in its critical review report. The result is that millions of older Americans are suffering unnecessarily when a safe and natural solution exists.

Hemp derived CBD is a powerful first step in restoring balance to the endocannabinoid system, but it is only part of the picture. Research shows that full spectrum cannabis extracts, which include a broader range of cannabinoids and terpenes, can work even more effectively. Complete concentrated cannabis oil, containing the full spectrum of natural endocannabinoids, may deliver the most profound results for certain patients. Expanding access to these therapies will be essential if we want to unlock the full healing potential of this plant.


The Economic and Social Impact

The video cites a powerful figure. A PricewaterhouseCoopers analysis estimates that fully integrating cannabis into the healthcare system could save the United States nearly 64 billion dollars annually. These savings reflect reduced pharmaceutical dependency, fewer hospitalizations, improved chronic disease outcomes, and enhanced quality of life for aging Americans. You can read more about PwC’s research on healthcare innovation here.

It is a financial argument, but it is also a moral one. Why should our elders endure pain, anxiety, and cognitive decline when nature has given us tools to help them live longer, happier, and healthier lives?


A Call to Action: Finish What the Farm Bill Started

The message concludes by crediting the 2018 Farm Bill, championed by President Trump, for legalizing hemp and laying the groundwork for today’s CBD market. The Farm Bill was just the first step.

Now the call is for bold next moves.

  • Educate doctors about the endocannabinoid system
  • Include CBD under Medicare coverage
  • Provide clear federal standards for CBD quality and dosing

These steps would constitute the most significant senior health reform in modern history, one that would transform aging and cement a powerful legacy for any administration that makes it happen.


What This Means for Future Cannabis Medicine

For those of us who have been in the cannabis community for decades, this is not just another news story. It is a signal that our movement is winning. A conversation that was once criminalized and censored is now being amplified by the President of the United States on his own platform.

It means the science is undeniable. It means the truth can no longer be buried. It means the wall of prohibition is cracking, not just legally, but culturally, scientifically, and politically.

It also means that everything we have been fighting for at 420 Magazine since 1993, education, access, healing, and justice, is finally moving full steam ahead. The President Trump CBD Cannabis Science Truth Social moment is proof that science and policy are finally converging.

Continue Reading

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News